Published in Br J Clin Pharmacol on August 01, 1995
Rapid dopamine transmission within the nucleus accumbens: dramatic difference between morphine and oxycodone delivery. Eur J Neurosci (2014) 1.51
Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br J Pharmacol (1996) 0.96
Role of active metabolites in the use of opioids. Eur J Clin Pharmacol (2008) 0.91
The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol (2000) 0.89
The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. Br J Clin Pharmacol (2002) 0.84
Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers. Eur J Clin Pharmacol (2007) 0.77
Differential effects of early postinjury treatment with neuroprotective drugs in a mouse model using diffuse reflectance spectroscopy. Neurophotonics (2015) 0.76
Blood-brain distribution of morphine-6-glucuronide in sheep. Br J Pharmacol (2006) 0.75
Sugar Derivatives of Morphine: A New Window for the Development of Potent Anesthetic Drugs. Nat Prod Bioprospect (2015) 0.75
Oral morphine and respiratory function amongst hospice inpatients with advanced cancer. Support Care Cancer (2003) 0.75
Methodological problems in the measurement of pain: a comparison between the verbal rating scale and the visual analogue scale. Pain (1975) 2.80
Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol (1993) 2.54
Analgesic effect of morphine glucuronides. Tohoku J Exp Med (1971) 2.02
Analgesic activity of morphine-6-glucuronide. Lancet (1988) 1.94
Arterialized ear lobe blood samples for blood gas tensions. Br J Dis Chest (1976) 1.93
Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain (1992) 1.89
The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther (1993) 1.81
Morphine-3-glucuronide--a potent antagonist of morphine analgesia. Life Sci (1990) 1.77
An experimental pain method sensitive to morphine in man: the submaximum effort tourniquet technique. J Pharmacol Exp Ther (1966) 1.70
Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther (1989) 1.64
Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth (1990) 1.63
Morphine-6-glucuronide, a potent mu agonist. Life Sci (1987) 1.55
Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J (Clin Res Ed) (1986) 1.49
Explanation for potency of repeated oral doses of morphine? Lancet (1987) 1.47
Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats. Life Sci (1988) 1.31
The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol (1992) 1.23
Reassessment of verbal and visual analog ratings in analgesic studies. Clin Pharmacol Ther (1985) 1.14
A comparison of the respiratory effects of meptazinol, pentazocine and morphine. Br J Anaesth (1979) 1.10
Clinical evaluation of mild analgesics: the measurement of clinical pain. Br J Clin Pharmacol (1980) 1.07
Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol (1987) 1.04
Multiple mu opiate receptors. Life Sci (1986) 1.00
Naloxazone, a long-acting opiate antagonist: effects on analgesia in intact animals and on opiate receptor binding in vitro. J Pharmacol Exp Ther (1980) 0.99
Explanation at the opioid receptor level for differing toxicity of morphine and morphine 6-glucuronide. Br J Cancer (1992) 0.97
Morphine-6-glucuronide: effects on ventilation in normal volunteers. Pain (1991) 0.90
Antagonism of morphine-induced respiratory depression with nalmefene. Br J Anaesth (1988) 0.85
Autoradiographic evidence for two classes of mu opioid binding sites in rat brain using [125I]FK33824. Peptides (1988) 0.82
Experimental pain produced by the submaximum effort tourniquet technique: further evidence of validity. J Pharmacol Exp Ther (1968) 0.81
Assessment of respiratory effects of analgesic drugs. Br J Anaesth (1968) 0.78
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 10.05
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax (2002) 8.77
Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax (1999) 8.63
Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 5.49
Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet (1993) 5.43
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 5.17
Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax (2000) 4.45
Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax (2002) 4.26
Major outpatient surgery. Lancet (1973) 3.83
Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ (1994) 3.52
The dynamics of change: cancer patients' preferences for information, involvement and support. Ann Oncol (1997) 3.50
COPD exacerbations: definitions and classifications. Eur Respir J Suppl (2003) 3.35
COPD exacerbations .1: Epidemiology. Thorax (2006) 2.94
Talking about cancer: how much is too much? Br J Hosp Med (1987) 2.67
Arterialised earlobe blood gas analysis: an underused technique. Thorax (1994) 2.48
Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2004) 2.24
Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med (1995) 2.20
Respiratory medicine: fighting for survival. BMJ (1992) 2.15
Supplemental oxygen during pulmonary rehabilitation in patients with COPD with exercise hypoxaemia. Thorax (2000) 2.06
Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J (2007) 2.03
Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J (2000) 2.00
Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J (2006) 1.94
Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J Immunol Methods (1992) 1.84
Relationship between depression and exacerbations in COPD. Eur Respir J (2008) 1.81
Appropriate chemotherapy for palliating advanced cancer. BMJ (1992) 1.80
Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J (2003) 1.78
European union standards for tuberculosis care. Eur Respir J (2012) 1.73
A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol (1989) 1.72
Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia. Thorax (1996) 1.69
An analysis of first-time enquirers to the CancerBACUP information service: variations with cancer site, demographic status and geographical location. Br J Cancer (1999) 1.68
Patterns of home mechanical ventilation use in Europe: results from the Eurovent survey. Eur Respir J (2005) 1.67
Portable oxygen therapy: assessment and usage. Respir Med (1991) 1.66
Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax (1998) 1.64
Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis (2006) 1.62
Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther (2000) 1.61
A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer (2002) 1.61
Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2003) 1.57
Airway infection accelerates decline of lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 1.56
Carboplatin or cisplatin? Lancet (1988) 1.53
Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J (2009) 1.52
Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol (1985) 1.51
Evaluation of pulsed dose oxygen delivery during exercise in patients with severe chronic obstructive pulmonary disease. Thorax (1999) 1.49
Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J (Clin Res Ed) (1986) 1.49
Using nasal intermittent positive pressure ventilation on a general respiratory ward. J R Coll Physicians Lond (1998) 1.48
An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med (1999) 1.46
Survival during exposure to the electrophilic reagent N-ethylmaleimide in Escherichia coli: role of KefB and KefC potassium channels. J Bacteriol (1997) 1.46
Modified incision for long saphenous vein harvest. Ann Thorac Surg (1998) 1.44
Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach? Br J Cancer (1991) 1.44
Pamidronate to reduce bone pain in normocalcaemic patient with disseminated prostatic carcinoma. Lancet (1989) 1.44
A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer (1991) 1.42
Assessment and follow up of patients prescribed long term oxygen treatment. Thorax (1993) 1.41
Systemic lupus erythematosus in Indian patients: prognosis, survival and life expectancy. Natl Med J India (1997) 1.41
Alternative cancer cures. Lancet Oncol (2000) 1.39
MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res (2005) 1.37
Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2004) 1.37
Adjuvant treatment for colorectal cancer. BMJ (1996) 1.36
State of the Art Compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. Can Respir J (2004) 1.35
Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine (1990) 1.35
Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Eur Respir J (1999) 1.27
Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer (1998) 1.26
The heterogeneity of chronic obstructive pulmonary disease. Thorax (2000) 1.25
Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Respir Med (2000) 1.24
Erythrapheresis in patients with polycythaemia secondary to hypoxic lung disease. Br Med J (Clin Res Ed) (1983) 1.23
Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax (2001) 1.21
Comparison of pressure and volume preset nasal ventilator systems in stable chronic respiratory failure. Eur Respir J (1993) 1.21
Sarcoidosis presenting with stroke. Stroke (1989) 1.20
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Is vitamin D deficiency important in the natural history of COPD? Thorax (2010) 1.18
Small intestinal perforation in Wegener's granulomatosis. Postgrad Med J (1982) 1.18
Home assessment of activities of daily living in patients with severe chronic obstructive pulmonary disease on long-term oxygen therapy. Eur Respir J (1997) 1.17
Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer (2003) 1.17
Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer (1993) 1.15
Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol (1996) 1.14
An improved method for the simultaneous determination of morphine and its principal glucuronide metabolites. J Chromatogr (1988) 1.14
Does long-term oxygen therapy affect quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia? Eur Respir J (1996) 1.11
Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol (1987) 1.11
Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J (2005) 1.10
Obstructive sleep apnea presenting as pseudopheochromocytoma: a case report. J Clin Endocrinol Metab (2004) 1.09
Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J (2010) 1.09
Morphine-6-glucuronide, an important metabolite. Lancet (1985) 1.08
Cancer information: a cost-effective intervention. Eur J Cancer (1999) 1.06
Nasal ventilation in acute exacerbations of chronic obstructive pulmonary disease: effect of ventilator mode on arterial blood gas tensions. Thorax (1994) 1.05
Overnight studies in severe chronic left heart failure: arrhythmias and oxygen desaturation. Br Heart J (1991) 1.04
A prospective study of 123I-labeled monoclonal antibody imaging in ovarian cancer. J Clin Oncol (1986) 1.03
Lancefield group F streptococci causing liver abscess and empyema. Indian J Med Res (1971) 1.02
The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet (1987) 1.00
Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis. Thorax (1996) 1.00
Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration. Cancer Res (1987) 1.00
Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol (1983) 0.99
A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol (1994) 0.99
FLT-3 ligand provides hematopoietic protection from total body irradiation in rabbits. Blood (1998) 0.99